(2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]-4-methylpentanoic acid

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]-4-methylpentanoic acid
• 化学式: C₂₂H₂₉FN₃O₉P
• 分子量: 529.5
• InChiKey: GVSBPWBIADNVDV-IJDMJUJQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  164
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• Process for preparing nucleoside prodrugs
  申请人：University College Cardiff Consultants Limited

  公开号：US10005810B2

  公开（公告）日：2018-06-26

  Provided are phosphoramidate nucleoside compounds of Formula (I), or pharmaceutically acceptable salts or esters or solvates thereof, useful in the treatment of cancer, viral infections and other diseases: Also provided is a process for the synthesis of the compounds of Formula (I) where a desired enantiomer, having regard to the asymmetric chiral center of the phosphorus atom P, is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb.

  本研究提供了可用于治疗癌症、病毒感染和其他疾病的式 (I) 磷酰胺核苷化合物或其药学上可接受的盐或酯或溶剂： 还提供了一种合成式（I）化合物的工艺，在该工艺中，根据磷原子 P 的不对称手性中心，可提供所需的对映体，且对映体的含量较高。该工艺包括在由选自铜、铁、喇和镱盐组成的金属盐催化剂存在下，将核苷与氯代磷酸盐混合。
• CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1-(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE
  申请人：Gilead Pharmasset LLC

  公开号：EP2552930B1

  公开（公告）日：2015-08-26
• PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS
  申请人：University College Cardiff Consultants Limited

  公开号：EP2920192A1

  公开（公告）日：2015-09-23
• MIXTURE OF RP/SP GEMCITABINE-[PHENYL-(BENZYLOXY-L-ALANINYL)]-PHOSPHATE
  申请人：University College Cardiff Consultants Limited

  公开号：EP3150616B1

  公开（公告）日：2017-05-10
• METHODS OF TREATING HEPATITIS C VIRUS INFECTION IN SUBJECTS WITH CIRRHOSIS
  申请人：Gilead Pharmasset LLC

  公开号：US20150150897A1

  公开（公告）日：2015-06-04

  Methods of treating hepatitis C virus infection in a subject with cirrhosis comprising administering to the subject an effective amount of Compound 1.